- Home
- NWBI vs TYRA Comparison
NWBI vs TYRA Comparison
Compare NWBI & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWBI | TYRA |
|---|---|---|
| Founded | 1896 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NWBI | TYRA |
|---|---|---|
| Price | $15.55 | $32.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $14.50 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 1.3M | 923.4K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.82% | N/A |
| EPS Growth | ★ 16.46 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.29 | N/A |
| Revenue Next Year | $5.06 | N/A |
| P/E Ratio | $46.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.25 | $9.96 |
| 52 Week High | $15.72 | $40.65 |
Technical Indicators
Market Signals| Indicator | NWBI | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 66.54 | 55.02 |
| Support Level | $11.81 | $29.68 |
| Resistance Level | N/A | $33.99 |
| Average True Range (ATR) | 0.25 | 1.85 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 83.17 | 69.02 |
Price Performance
Historical ComparisonAbout NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution, offering personal and commercial banking solutions, business services, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and Commercial Banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Commercial Banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.